Merck Wins FDA Expansions, Posts Positive HIV Data, Halts Lung Cancer Trial

Merck (NYSE:MRK) announced a series of developments including expanded FDA approvals for KEYTRUDA and CAPVAXIVE, positive Phase 3 data for a once-weekly oral HIV treatment in collaboration with Gilead (NASDAQ:GILD), and the discontinuation of a Phase 3 lung cancer trial.

Regulatory Approvals

Merck received FDA approval for expanded use of KEYTRUDA and KEYTRUDA QLEX with WELIREG as adjuvant treatment in certain renal cell carcinoma patients. The FDA also granted expanded approval for CAPVAXIVE in children and adolescents at higher risk for pneumococcal disease, making it the only PCV indicated for this US group.

HIV Data

Merck and Gilead reported positive Phase 3 data for a once-weekly oral HIV treatment regimen. The new regimen shows comparable efficacy to current daily treatments, potentially improving adherence.

Lung Cancer Trial Halt

Merck discontinued a Phase 3 lung cancer trial without providing details on the reasons. The decision is likely due to insufficient efficacy or safety concerns.

What This Means for Investors

The regulatory approvals and positive HIV data present growth opportunities for Merck and Gilead in oncology, vaccines, and HIV markets. While the lung cancer trial halt may negatively impact Merck's pipeline outlook, its diversified portfolio mitigates risks.